Physician profile
Thomas Elmer
NPI 1255335907
$21,353.47
in general payments reported to CMS, 2019-2025
29 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,785 · 2020: $3,863 · 2021: $8,791 · 2022: $1,511 · 2023: $1,273 · 2024: $1,805 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,903 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,903.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11,193.11 | 2019-2021 | |
| Alcon Vision LLC | $2,599.23 | 2019-2025 | Dailies Total1, Precision 1, Air Optix Color |
| Abbvie INC. | $1,229.76 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $1,020.86 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $1,004.30 | 2022-2025 | Victus, Miebo, Xiidra |
| Carl Zeiss Meditec USA, INC. | $900.53 | 2021-2024 | Visumax |
| Sun Pharmaceutical Industries INC. | $447.26 | 2019-2025 | Cequa |
| Allergan, INC. | $375.94 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $359.87 | 2019-2021 | |
| Sight Sciences, INC. | $310.59 | 2019-2025 | Omni Surgical System |
| Ivantis, INC | $267.04 | 2019-2021 | |
| Omeros Corporation | $242.52 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $215.24 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $162.52 | 2022-2024 | Tyrvaya |
| Glaukos Corporation | $153.90 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $152.23 | 2020-2022 | |
| Rxsight INC | $126.79 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Rayner Intraocular Lenses Limited | $125.00 | 2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Novartis Pharmaceuticals Corporation | $84.48 | 2020-2021 | |
| Ocular Therapeutix, INC. | $62.43 | 2020-2025 | Dextenza |
| Biotissue Holdings INC. | $58.02 | 2020-2023 | |
| Mallinckrodt Hospital Products INC. | $56.29 | 2021 | |
| Beaver-Visitec International, INC. | $49.07 | 2023-2025 | |
| Apellis Pharmaceuticals, INC. | $48.07 | 2023 | |
| Carl Zeiss Meditec, INC. | $36.11 | 2024 | |
| Amgen INC. | $21.50 | 2025 | Tepezza |
| Thea Pharma INC. | $19.06 | 2023 | Iyuzeh |
| Convatec INC. | $17.16 | 2023 | |
| Aerie Pharmaceuticals, INC. | $14.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Elmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.